Patients with COPD and type 2 inflammation were found to have less disease after receiving dupilumab.

Published Date: 21 Jun 2023

Patients with type 2 inflammation of chronic obstructive pulmonary disease experienced quick and long-lasting improvements in their condition following treatment with the monoclonal antibody dupilumab, according to a 12-month Phase 3 clinical trial.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Year in Review: Chronic Lymphocytic Leukemia

2.

According to a study, white Americans are overdiagnosing melanoma at an alarming rate.

3.

Approval in Endometrial Cancer Expanded; Masks at Cancer Centers; NPR Reporter Dies

4.

The First Gene Therapy Provides a Durable Response for Non-Muscle-Invasive Bladder Cancer.

5.

Canine Cancer Vaccine: A Potential Resurrection? U.S. KK. Snubs Enertu.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot